← Human Trials & Peer-Reviewed Studies
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
Plain-language guide to PMID 25980900 (2015): randomized controlled trial study of Liraglutide.
Key Facts
- PMID
- 25980900
- Journal
- Diabetes, obesity & metabolism
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Gough SC et al. (8 authors)
- DOI
- 10.1111/dom.12498
- Registered trial
- NCT01336023
What This Study Did, in Plain Language
What Was Tested
Researchers studied Liraglutide in this randomized controlled trial publication.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.
How the Study Was Run
In design terms this was a randomized study.
The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin, Long-Acting.
Author keywords: diabetes therapy, hypoglycaemia, insulin degludec and liraglutide.
What This Means in Plain Language
The paper is a randomized study of Liraglutide.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2015 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Liraglutide compound page, all human trials.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.